Endometrial Cancer Trial, Recruiting NCT04839614 Sponsor: Dana-Farber Cancer Institute Condition: Endometrial Cancer
Back to Endometrial Cancer

Endometrial Cancer Trial, Recruiting

NCT04839614
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adult women aged 18 or older.
  • People with a body mass index (BMI) between 35 and 39.99, plus at least one serious weight-related health condition — such as type 2 diabetes, high blood pressure, high cholesterol, sleep apnea, liver disease, acid reflux, asthma, severe urinary leakage, debilitating joint problems, or significantly reduced quality of life — OR a BMI of 40 or above.
  • People who have received a tissue-based diagnosis (usually from an endometrial biopsy) confirming either early-stage (grade 1) uterine cancer or a pre-cancerous condition called endometrial intraepithelial neoplasia (EIN).

Who may not be able to join:

  • People under 18 years of age.
  • People with a BMI below 35.
  • People who do not have a tissue-based diagnosis, or whose tissue diagnosis shows a more advanced uterine cancer (grade 2 or higher).
  • People who are currently pregnant.
  • People for whom bariatric (weight-loss) surgery would not be considered safe — this includes current smokers, people who have previously had bariatric surgery, people with active substance use issues, a recent suicide attempt, an eating disorder called bulimia nervosa, large abdominal hernias, or a psychiatric illness that is not well managed.
  • People who are unable to read an English-language consent form, or who are unwilling to provide informed consent.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 15 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Colleen Feltmate, MD, Brigham and Women's Hospital

Phone: 617-732-8840

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
1 August 2021
Est. completion
30 June 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

proportion of patients who schedule an appointment and speak with a surgeon 1-2 weeks after enrollment; proportion of patients who undergo the concurrent surgeries within 8 weeks of diagnosis (12 weeks for EIN patients)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov